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Abstract:
Background: Some oncogenes such as ERBB2 and EGFR are over-expressed in only a subset of patients. Cancer outlier profile analysis 
is one of computational approaches to identify outliers in gene expression data. A database with a large sample size would be a great 
advantage when searching for genes over-expressed in only a subset of patients.
Description: GENT (Gene Expression database of Normal and Tumor tissues) is a web-accessible database that provides gene expres-
sion patterns across diverse human cancer and normal tissues. More than 40000 samples, profiled by Affymetrix U133A or U133plus2 
platforms in many different laboratories across the world, were collected from public resources and combined into two large data sets, 
helping the identification of cancer outliers that are over-expressed in only a subset of patients. Gene expression patterns in nearly 1000 
human cancer cell lines are also provided. In each tissue, users can retrieve gene expression patterns classified by more detailed clinical 
information.
Conclusions: The large samples size (.24300 for U133plus2 and .16400 for U133A) of GENT provides an advantage in identifying 
cancer outliers. A cancer cell line gene expression database is useful for target validation by in vitro experiment. We hope GENT will be 
a useful resource for cancer researchers in many stages from target discovery to target validation. GENT is available at http://medical 
genome.kribb.re.kr/GENT/ or http://genome.kobic.re.kr/GENT/.
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Background
Recent  examples  of  successful  cancer  therapeutics 
such as Gleevec, Herceptin, and Iressa suggest that 
the concept of ‘molecular targeted therapy’ is appli-
cable to human cancers of diverse tissue and genetic 
origin.1 ‘Oncogene addiction’ is a term to describe 
a phenomenon in which the growth and survival of 
tumors are impaired by the inactivation of a single 
oncogene.2  There  are  several  established  relation-
ships  between  genetic  alterations  and  correspond-
ing targeted therapies, and efforts to identify further 
genetic  alterations  are  underway.  Mechanisms  of 
genetic alterations include mutations (EGFR in lung 
cancer), translocations (BCR-ABL in chronic myeloid 
leukemia), and gene amplifications (ERBB2 in breast 
cancer).1
Interestingly, some oncogenes are altered in only 
a subset of cancer patients. For examples, ERBB2 is 
amplified and over-expressed in about 25%–30% of 
breast cancer patients, whereas EGFR is mutated in 
about 20% of lung cancer patients. Cancer Outlier 
Profile Analysis (COPA) is a computational method 
that identifies gene expression profiles that are patho-
genically over-expressed in only a subset of patients.3,4 
AGTR1 is an example of potential target genes identi-
fied by applying the COPA method to the Oncomine 
database.5
A  database  with  a  large  sample  size  is  a  great 
advantage when searching for genes over-expressed 
in only a subset of patients. For example, identify-
ing genes over-expressed in 50 out of 1000 patients 
is  easier  and  more  reliable  than  identifying  genes 
over-expressed in 2 out of 40 patients. Although the 
sample size of most individual gene expression stud-
ies rarely exceeds one thousand, a data set of nearly 
ten thousand samples (ie, GeneSapiens database) can 
be created by a combined analysis of multiple data 
sets.6 Recent work has shown that analysis of a large 
microarray data set compiled from many data sets can 
reveal novel findings that are difficult to observe in 
the individual studies.7 For a combined analysis, data 
sets created by the Affymetrix platforms (ie, U133A 
and U133plus2) offer several advantages. First, most 
gene expression data sets have been created using the 
Affymetrix  platforms.  Second,  many  data  sets  are 
accompanied by raw CEL files so that users can pre-
process them as they wish. We have collected human 
tissue gene expression data sets produced using the 
Affymetrix U133A and U133Plus2 platforms from 
public resources, and built a large-scale gene expres-
sion database of more than 40,000 samples.
construction and content
More  than  24300  (U133plus2;  306  data  sets)  and 
16400 (U133A, 241 data sets) samples were collected 
from  public  resources,  including  Gene  Expression 
Omnibus,8  Array  Express,9  and  Expression  Project 
for Oncology.10 Whenever CEL files were available 
(288/306 for U133plus2 and 192/241 for U133A), we 
pre-processed them using the MAS5 algorithm using 
the  affy  package.11  We  chose  the  MAS5  algorithm 
because it is a single-array algorithm in which expres-
sion values are independent of other data. We then 
normalized each sample to a target density of 500. For 
data sets without CEL files but pre-processed by the 
MAS5 algorithm (18/306 for U133plus2 and 49/241 
for  U133A),  we  used  expression  measures  down-
loaded from the web source and normalized them to a 
target density of 500. We identified samples described 
in more than one dataset, and cleaned them up from 
duplications. We then classified each sample according 
to tissue and disease types (Table 1) based on informa-
tion given in each dataset. Most samples (∼75%) were 
classified into either cancer or normal, but about 20% 
of samples were classified into other diseases including 
neurodegenerative diseases, immune-related diseases, 
and organ-specific diseases. In each tissue type, we 
also classified each sample into more detailed clinical 
subtypes such as estrogen receptor positive breast can-
cers or high grade serous carcinoma of the ovary etc, as 
described in the original data source. We also collected 
expression  data  for  more  than  3000  samples  com-
prising nearly 1000 different cancer cell lines across 
tissues, and processed them using the same method 
(Table 2). Broad/Sanger Cell Line Project12 and GSK’s 
cell line project13 provided the most abundant expres-
sion data sets. For genes with multiple Affymetrix ids, 
we calculated the average of the multiple probes. The 
system implementation is based on an Apache web 
server, JavaScript and PHP scripts for data processing, 
Open flash charts and R scripts for image production, 
and MySQL as a backend database.
Utility and Discussion
GENT can be searched using either a gene symbol 
or an Affymetrix id. DB search results are presented Gene expression database of normal and tumor tissues
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  international   multi-center study showed the effective-
ness of Herceptin in patients with ERBB2-positive 
stomach cancer patients.14
The pattern of ERBB2 expression in diverse cell 
lines provides interesting information as well. First, 
similar patterns are observed between cancer cell lines 
and tissues (Figs. 1 and 2). The ERBB2 is not only 
over-expressed in a subset of breast, lung, ovary, and 
gastric tumor tissues, but it is also over-expressed in 
a subset of cell lines from those four tissues (Fig. 2). 
Second, information on its expression in specific cell 
lines is provided as raw data for convenience during 
in vitro experiments. Here, HCC1954 or B-BT-474 
(breast), SKOV3 (ovary), and NCI-N87 or MKN7 
(stomach) are good cell lines for observing the effects 
of siRNA knock-down of the ERBB2, a first step to 
Table 1. The number of tissue samples according to tissue types (U133plus2 and U133A).
Tissue U133plus2 U133A Total
cancer normal cancer normal
Abdomen 13 0 0 0 13
Adipose 1 59 0 12 72
Adrenal gland 14 5 0 0 19
bladder 39 14 87 15 155
blood 4693 639 3130 1099 8974
brain 785 568 592 1627 3572
breast 1954 251 2635 91 4931
Cervix 74 12 64 34 184
Colon 1294 206 256 27 1783
endometrium 72 61 0 9 142
esophagus 48 9 24 28 109
GIST 64 0 0 0 64
Head and neck 202 14 21 2 239
Heart 0 0 0 41 41
Kidney 573 105 366 66 1110
Liver 182 25 156 52 415
Lung 441 225 582 364 1612
Muscle 0 177 0 331 508
Myometrium 0 0 0 24 24
Ovary 859 21 341 9 1230
Pancreas 132 55 13 8 208
Prostate 308 45 244 83 680
Sarcoma 493 0 0 0 493
Skin 290 28 499 59 876
Small intestine 13 6 0 22 41
Stomach 268 57 46 18 389
Testis 4 6 184 13 207
Thyroid 62 25 44 25 156
Tongue 0 11 0 4 15
Uterus 155 12 0 24 191
vagina 3 5 0 0 8
vulva 21 14 0 0 35
Total 13057 2655 9284 4087 29083
in  one  of  three  ways:  1)  cancer-normal  samples 
across tissues 2) cancer cell lines across tissues, and 
3) detailed phenotypes in a tissue of choice. Raw data 
for the searched gene are available for download, so 
users can analyze them as they wish. Users can search 
multiple gene symbols or Affymetrix ids for cancer-
normal samples across tissues.
As  an  example,  we  show  a  pattern  of  ERBB2 
expression  in  diverse  cancer  and  normal  tissues 
(Fig. 1) and in diverse cancer cell lines (Fig. 2). As 
expected, the over-expression of ERBB2 in a subset 
of breast cancer patients is obvious. Besides, over-
expression of ERBB2 in a subset of lung, ovarian, 
and  stomach  cancer  patients  is  observed  as  well. 
Indeed,  Herceptin  is  being  tested  in  the  treatment 
of lung, ovarian, and stomach cancer; Last year, an Shin et al
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show if it is a critical oncogene (Fig. 2). The informa-
tion provided by the cell line database allows users to 
skip laborious RT-PCR steps necessary for selecting 
cell lines for in vitro experiments.
As a second example, we show a pattern of MET 
expression in diverse normal and tumor tissues. MET 
is a tyrosine kinase receptor for hepatocyte growth 
factor and its mutations and amplifications are associ-
ated with papillary renal carcinoma.1 Again, the over-
expression of MET in a subset of renal cancers is 
clearly shown (Supplementary Fig. 1). Besides, MET 
is over-expressed in a subset of liver, melanoma, and 
gastric cancer patients, suggesting that MET can be 
a target for a subset of liver, melanoma and gastric 
cancer patients.
Finally, users can search detailed phenotypes in 
a specific tissue of interest. For example, if a user 
selects a brain tissue for detailed information, pat-
terns of expression in diverse brain diseases including 
Alzheimer’s disease, Parkinson’s disease, and sub-
types of brain tumors are presented. We provide an 
example of ovarian data set (GSE12172) in   Figure 3. 
Here, ovarian cancer is further classified into subtypes 
based on tumor stages. We parsed detailed clinical 
information given in each data set and provide them 
in a user-friendly manner.
One may be concerned that the GENT database 
may present false findings due to noise in the pub-
lic data because laboratory effects are known to be 
present in publicly available data sets.11 We assessed 
the  impact  of  these  effects  following  Lukk  et  al’s 
  analyses.7 We  selected  biological  groups  (with  ten 
replicates or more) which contain at least two differ-
ent laboratories. For U133A data sets, we selected 
5,089 samples of 92 biological groups produced in 
93 laboratories. For each of the biological groups, we 
computed the average correlation coefficient between 
the assays from different laboratories within the same 
group.  We  also  calculated  the  average  correlation 
coefficient  between  assays  from  the  same  labora-
tory but belonging to different biological groups. The 
comparison of the two similarity distributions showed 
that the biological effects were stronger than the labo-
ratory effects7 (Fig. 4). We got similar results with the 
U133Plus2 data sets, too.
Also, we provide three means to help to identify and 
minimize false positive findings. First, raw data are 
provided for the searched gene with data sources (gene 
expression series id) so that users can check laboratory 
effects themselves. Second, a data set filtering option is 
provided so that users can include or exclude particu-
lar data sets. Finally, in our opinion, providing results 
separately in two platforms (U133A and U133plus2) 
is one way to discern between true and noisy data as 
congruent results between the two platforms are a sign 
of good data quality (Figs. 1 and 2).
The COPA method was originally developed to 
identify genomic aberrations (ie, chromosomal trans-
locations such as TMPRSS2-ETV1) by searching for 
pairs of samples with mutually exclusive outliers.4 
Currently,  the  Oncomine  database  implements  the 
Table  2. The  number  of  cancer  cell  lines  according  to 
  tissue types (U133plus2 and U133A).
Tissue U133plus2 U133A Total
Adrenal gland 0 2 2
biliary tract 0 6 6
bladder 30 40 70
blood 229 142 371
bone 12 32 44
brain 149 117 266
breast 239 199 438
Cervix 23 23 46
Colon 143 56 199
Connective tissue 9 0 9
endometrium 0 11 11
esophagus 12 25 37
ewT 7 0 7
eye 5 2 7
Kidney 29 40 69
Leukemia 0 4 4
Liver 33 16 49
Lung 358 325 683
Lymphoma 73 1 74
Muscle 10 0 10
Myeloma 7 24 31
Ovary 24 43 67
Pancreas 50 18 68
Pharynx 6 0 6
Placenta 9 2 11
Prostate 12 18 30
Rectum 7 0 7
Sarcoma 8 0 8
Skin 129 73 202
Soft tissue 0 19 19
Stomach 56 24 80
Testis 0 4 4
Thyroid 12 13 25
Upper aerodigestive 0 24 24
Urinary tract 0 20 20
vulva 9 3 12
Total 1714 1336 3050Gene expression database of normal and tumor tissues
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COPA method and provides information on possible 
outliers. Basically, samples in a dataset are grouped 
by sample properties, centered by a median value and 
rescaled  by  median  absolute  deviation,  and  COPA 
score is calculated at multiple percentiles (ie, 1%, 5%, 
and 10%). Although we adopted COPA concept in the 
GENT database, we didn’t implement it as suggested 
in the original paper.3,4 Instead, we tried to increase 
the sample size by collating similar samples across 
different datasets, so outliers could be detected more 
reliably. We plan to add the COPA score for each gene 
in the future. Also, we plan to add additional genomic 
data such as copy number alterations and genome-
wide DNA methylation data to the GENT database 
so  that  additional  information  can  be  obtained  by 
the integrated analysis of multiple genomic data. We 
also plan to add gene expression data generated using 
other  platforms  (ie,  Illumina  or  Agilent)  as  more 
Figure 1. Pattern of ERBB2 expression across diverse normal and tumor tissues, A) U133plus2 data set, B) U133A data set.Shin et al
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Figure 3. Pattern of LAMB3 expression among ovarian cancer subtypes. A) A screenshot of sub-type specific search option. B) Pattern of LAMB3 
  expression in different stages of ovarian cancer patients from GSe12172 data set.
Figure 2. Pattern of ERBB2 expression across diverse cancer cell lines in U133plus2 data. A) Data is shown as multiple boxplots. B) Data is shown as a 
flash chart so users can identify a cell line name by pointing a mouse on each dot.Gene expression database of normal and tumor tissues
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data accumulate. Finally, we plan to add more func-
tions to provide more extensive clinical information 
which is currently provided in a limited way.
conclusions
Oncomine5  and  Gene  Expression  Atlas15  are  two 
examples of excellent web databases for gene expres-
sion  information  with  many  useful  functions.  The 
two  databases  provide  extensive  clinical  informa-
tion given in each collected dataset and many use-
ful  search  options. To  mention  a  major  difference 
between  the  two  databases,  Oncomine  focuses  on 
human cancer datasets while Gene Expression Atlas 
comprises more than 20 organisms including human, 
mouse, rat, and so on. As those two databases pro-
vide rich information, we focused on providing new 
features for users instead of implementing features 


















Figure 4. Analysis of laboratory effects by comparing distribution of correlation coefficients among three different groups: Distribution of all pairwise cor-
relations between the samples in the dataset (black), distribution of average similarities between the sample subgroups from different laboratories within 
the same biological group (green), distribution of average similarities between the sample subgroups from different biological groups within the same 
laboratory (red).
  opinion, two aspects of GENT are unique. The first 
one is the large sample size made possible by the col-
lation of hundreds of datasets into two large datasets, 
and the second one is the cancer cell line gene expres-
sion database which is a convenient tool to select cell 
lines of interest. The large sample size (.24300 for 
U133plus2 and .16400 for U133A) of GENT pro-
vides an enormous advantage in identifying cancer 
outliers. A cancer cell line gene expression database 
is a useful resource for target validation by in vitro 
experiment. We hope GENT will be a useful resource 
for cancer researchers in many stages from target dis-
covery to target validation.
Availability and Requirements
The  GENT  database  is  freely  available  at  http:// 
medical-genome.kribb.re.kr/GENT/ or http://genome.
kobic.re.kr/GENT/.Shin et al
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GENT,  Gene  Expression  database  of  Normal 
and  Tumor  tissues;  COPA,  Cancer  Outlier  Profile 
Analysis.
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Figure s1. Pattern of MET expression across diverse normal and tumor tissues.
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